Adherent systems for viral vector production

Viral vectors are crucial gene delivery vehicles for cell and gene therapy purposes. This decade has witnessed advancement of clinical trials from Phase 1 to Phase 3 and regulatory approval of a few AAV and CAR-T-based therapies. In the case of gene therapy using AAV, wherein the drug product itself is a vector, the regulatory requirements are more stringent than for CAR-X cell therapies using lentiviral vector, where the vector acts as a critical raw material or gene modifying agent. Hence the demand has increased for both research grade and GMP grade viral vectors. Ease of multi-plasmid transfection, scalability, fully characterized cGMP cell lines, and single-use and closed systems for large-scale production are crucial to the production of these viral vectors. Adherent systems were classically utilized for viral vector production and are still in use.

Please enter your email to access content Read now